Evidence map›Paper›PMID 31201421›Full record

ArticlePathogens and disease2019

Evaluation of a PGP3 ELISA for surveillance of the burden of Chlamydia infection in women from Australia and Samoa.

Rami Mazraani, Peter Timms, Philip C Hill, Tamaailau Suaalii-Sauni, Tavita Niupulusu, Seiuli V A Temese, Liai Iosefa-Siitia, Leveti Auvaa, Siuomatautu A Tapelu, Maauga F Motu and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens and disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. UnveilingiScience · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Rami MazraaniSchool of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Peter TimmsFaculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Maroochydore, QLD 4558, Australia.
Philip C HillCentre for International Health, University of Otago, Dunedin, 9016, New Zealand.
Tamaailau Suaalii-SauniSchool of Languages and Cultures, Victoria University of Wellington, Wellington, 2820, New Zealand.
Tavita NiupulusuSamoa Cancer Society, Moto'otua Street, Apia, Samoa.
Seiuli V A TemeseCentre for Samoa Studies, National University of Samoa, Le Papaigalagala Campus, To'omatagi, Samoa.
Liai Iosefa-SiitiaSamoa Family Health Association, Apia, Samoa.
Leveti AuvaaNational Department of Health, Apia, Samoa.
Siuomatautu A TapeluSamoa Cancer Society, Moto'otua Street, Apia, Samoa.
Maauga F MotuSamoan National Council of Churches, Apia, Samoa.
Antoinette RighartsPreventive and Social Medicine, Dunedin School of Medicine, The University of Otago, Dunedin, 9016, New Zealand.
Michael S WalshPlanning, Funding and Health Outcomes, Waitemata and Auckland District Health Boards, Auckland, New Zealand.
Luk RombautsMIMR-PH Institute of Medical Research, Monash, Australia.
John A AllanUC Health Clinical School, The Wesley Hospital, Auchenflower, Queensland, 4066, Australia.
Patrick HornerPopulation Health Sciences, University of Bristol, Bristol, United Kingdom.
Wilhelmina M HustonSchool of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
National University of Samoa · WSUniversity of Otago · NZUniversity of Technology Sydney · AUAuckland District Health Board · NZMonash Institute of Medical Research · AUUniversity of Bristol · GBUniversity of the Sunshine Coast · AUVictoria University of Wellington · NZWesley Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serological assays can be used to investigate the population burden of infection and potentially sequelae from Chlamydia. We investigated the PGP3 ELISA as a sero-epidemiological tool for infection or sub-fertility in Australian and Samoan women. The PGP3 ELISA absorbance levels were compared between groups of women with infertility, fertile, and current chlamydial infections. In the Australian groups, women with chlamydial tubal factor infertility had significantly higher absorbance levels in the PGP3 ELISA compared to fertile women (P < 0.0001), but not when compared to women with current chlamydial infection (P = 0.44). In the Samoan study, where the prevalence of chlamydial infections is much higher there were significant differences in the PGP3 ELISA absorbance levels between chlamydial sub-fertile women and fertile women (P = 0.003). There was no difference between chlamydial sub-fertile women and women with a current infection (P = 0.829). The results support that the PGP3 assay is effective for sero-epidemiological analysis of burden of infection, but not for evaluation of chlamydial pathological sequelae such as infertility.

Indexed as

Epidemiological MonitoringAdolescentAdultAntigens, BacterialAustraliaBacterial ProteinsChlamydiaChlamydia InfectionsEnzyme-Linked Immunosorbent AssayFemaleHumansMiddle AgedSamoaSeroepidemiologic StudiesSerologic TestsYoung AdultAntigens, BacterialBacterial Proteinspgp3 protein, ChlamydiachlamydiaELISASero-epidemiologyserologySub-fertilitytubal factor infertility

Identifiers

PMID31201421
PMCPMC6607412
OpenAlexW2949413343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.